Six big U.S. pharmaceuticals giants are set to report Q4 earnings in coming days, and Credit Suisse analyst Vamil Divan just released a report previewing what traders can expect. Starting on Jan. 26, Johnson & Johnson JNJ, Eli Lilly and Co LLY, Bristol-Myers Squibb Co BMY, AbbVie Inc ABBV, Pfizer Inc. PFE and Merck & Co., Inc. MRK all report earnings within a one-week stretch.
Overall, Divan expects that the market will be most concerned with the path forward for these companies. “We expect investor focus to be primarily on company guidance and commentary around 2016 as opposed to the actual 4Q 2015 results,” he explained.
Related Link: Credit Suisse Initiates On Smid-Cap Biotechs, Reveals Favorite Stock Picks
While the firm is bullish on the space overall, it remains cautious on Merck, which is facing new generic competition for Vytorin/Zetia in 2017.
Headed into earnings season, Credit Suisse has an Outperform rating on AbbVie, Bristol Myers, Eli Lilly and Pfizer. The firm maintains a Neutral rating on J&J and Merck.
Disclosure: the author holds no position in the stocks mentioned.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
